Abstract 12135: Quality of Life in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
Catherine G. Ireland(Brigham and Women's Hospital), Carolyn Y. Ho(Brigham and Women's Hospital), Anna Axelsson Raja(Copenhagen University Hospital), Ivan Wilmot(Cincinnati Children's Hospital Medical Center), Joseph W. Rossano(Children's Hospital of Philadelphia), Alexandre C. Pereira(University of Washington), E. John Orav(Harvard University), Anjali Owens(University of Pennsylvania), Jonathan H. Soslow(Vanderbilt University Medical Center), Patel R Amit(University of Chicago), Henning Bundgaard(Copenhagen University Hospital), Matthew T. Wheeler(Stanford University), Kenneth Zahka(Cleveland Clinic), Jason R. Becker(University of Pittsburgh), Matthew R.G. Taylor(University of Colorado Anschutz Medical Campus), Luisa Mestroni(University of Colorado Anschutz Medical Campus), Sharlene M. Day(University of Pennsylvania), Richard G. Bach(Washington University in St. Louis), Mark W. Russell(Andover Eye Associates), Charles E. Canter(St. Louis Children's Hospital)
Cited by 0
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Truncations of Titin Causing Dilated Cardiomyopathy
|New England Journal of Medicine|2012|1.5k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands
|Nature Genetics|2017|930